In May, I wrote an article on Cytokinetics (NASDAQ:CYTK) detailing why it still shows value potential despite setbacks. I have now been following Cytokinetics for over a year and a half, monitoring both clinical developments and the technical picture. I am a physician (board certified in Child Psychiatry, Psychiatry, and Pediatrics) and familiar with medical literature.
Today, I am writing to update Cytokinetics' progress with both additional clinical data as well as the technical performance of the stock.
Additional Data on Tirasemtiv
Cytokinetics has released several sets of additional pre-defined data sets on June 2nd, June 13th, and July 10th.
June 2nd Data
The headline to the June 2nd data was that the positive effects of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|